Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jakub Kosma Rokicki has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic Yield and Clinical Consequences of Implantable Loop Recorder Monitoring in a Real-World Tertiary Cardiovascular Center Under Restricted Reimbursement

    by Jakub Kosma Rokicki, Maria Boszko, Marcin Michalak, Patryk Pindlowski, Andrzej Cacko, Piotr Wieniawski, Marcin Grabowski

    Background/Objectives: Implantable loop recorders (ILRs) provide prolonged, remotely monitored rhythm surveillance, but restricted reimbursement limits access in several healthcare systems, including Poland. We evaluated the safety and diagnostic yield of ILR monitoring in a tertiary center without dedicated reimbursement. Methods: We retrospectively analyzed consecutive patients undergoing ILR implantation (March 2013–November 2023); all devices were remotely monitored. The primary endpoint was an arrhythmia-driven management change (a management change resulting from an ILR-documented arrhythmia), analyzed per patient and per implantation episode. Results: Fifty patients (median age 58.1 years; 52.0% female) underwent 51 implantations, mostly for unexplained syncope (82.4%). The median symptom-to-implantation interval was 36 (interquartile range [IQR] 9–102) months. Over a median of 1290 (IQR 507–1519) monitoring days, clinically relevant arrhythmias were detected in 35 patients (70.0%). An arrhythmia-driven management change occurred in 21 patients (42.0%, 95% confidence interval 29.4–55.8%; Kaplan–Meier estimate 26.1% at 12 months), and every underlying arrhythmia was first identified by remote monitoring. These changes comprised cardiac implantable electronic device implantation in 13 patients (26.0%), catheter ablation in 4 (8.0%) and pharmacotherapy modification in 8 (16.0%). There were no acute procedural complications; pocket infection required explantation of 2 devices, and one non-cardiac death occurred. Conclusions: In this selected cohort under restricted reimbursement, remotely monitored ILR surveillance had an acceptable safety profile and led to an arrhythmia-driven management change in more than two in five patients. These single-arm data cannot quantify the effects of reimbursement policy or remote monitoring but support prospective comparative and economic evaluation of broader ILR access.

  • Open Access

    Epicardial ventricular tachycardia ablation beside a substernal extravascular implantable cardioverter-defibrillator lead: a case report

    by Maria Zaborska-Dworak, Jakub K Rokicki, Marcin Michalak, Marcin Grabowski, Michał Peller

    Structured Background: The extravascular implantable cardioverter-defibrillator (EV-ICD) places a single defibrillation lead in the substernal space, retaining antitachycardia pacing and defibrillation without intravascular hardware. As EV-ICD use increases, a larger proportion of patients requiring epicardial access for ventricular tachycardia (VT) ablation will have an EV-ICD in situ; the substernal lead lies along the epicardial-access corridor, where subxiphoid puncture risks injuring it. Case summary: A 56-year-old man with prior inferior myocardial infarction (chronically occluded circumflex artery) and left-ventricular ejection fraction 39% presented with haemodynamically unstable monomorphic VT and received an EV-ICD for secondary prevention. Combined endocardial–epicardial ablation was performed. With device detection off, epicardial access was obtained percutaneously by carbon-dioxide insufflation through a coronary-vein branch and subxiphoid puncture into the gas-filled pericardial space, away from the substernal lead. High-density mapping showed inferolateral and basal-septal low-voltage areas; endocardial and epicardial radiofrequency applications abolished late potentials and rendered VT non-inducible. The lead was undamaged: high-voltage impedance was 100 Ω before and 95 Ω after ablation, with unchanged sensing, pacing impedance and no effusion. No sustained VT recurred over three months. Discussion: Epicardial VT ablation can be performed safely alongside a substernal EV-ICD lead. Percutaneous carbon-dioxide-assisted coronary-vein-exit access opens a controlled pericardial plane away from the lead, mitigating the principal hazard of mechanical lead injury without the surgical access or lead manipulation described previously, and offers a transferable workflow with documented lead integrity.

  • Open Access

    Predictors of Appropriate Implantable Cardioverter-Defibrillator Intervention in Adults with Congenital Heart Disease

    by Jakub Malinowski, Łukasz Nowotka, Jakub Kosma Rokicki, Olgierd Woźniak, Paweł Syska, Michał Lewandowski, Artur OręZiak, Joanna Zakrzewska-Koperska, Patryk Marchewka, Anna Jargieło, et al.

    Background: Evidence to guide risk stratification after ICD implantation in adults with congenital heart disease (ACHD) is limited. We sought predictors of appropriate ICD intervention in this population. Methods: Consecutive ACHD patients implanted with an ICD (2009–2023) were analysed retrospectively. Time to first appropriate ICD intervention was modelled from a single, consistently defined start of observation. Because only 24 events were available, candidate predictors were pre-specified and each model limited to two covariates; sparse predictors used Firth penalisation, and multiplicity was addressed by the Benjamini–Hochberg false discovery rate procedure. Results: Among 56 patients (73.2% male; 22 primary and 34 secondary prevention), appropriate intervention occurred in 24 (42.9%) over a median follow-up of 51.9 months. Atrial fibrillation (HR 2.75, 95% CI 1.22–6.23) and radiographic cardiomegaly (HR 3.99, 95% CI 1.28–12.40) showed the largest unadjusted associations, whereas individual congenital lesions and disease-severity descriptors did not. No predictor remained significant after Benjamini–Hochberg correction (q ≈ 0.10). The very high hazard ratios for sparsely represented thyroid disorders (hypothyroidism, n = 2; hyperthyroidism, n = 4) were unstable under penalised estimation and are reported as exploratory. A pre-specified two-variable model (atrial fibrillation plus radiographic cardiomegaly) showed modest discrimination (optimism-corrected Harrell’s C-index 0.63). Conclusions: In a heterogeneous real-world ACHD cohort, a history of atrial fibrillation and radiographic cardiomegaly were associated with appropriate ICD intervention. Given the small number of events and the sparsity of several predictors, these findings should be regarded as hypothesis-generating and require validation in larger multicentre ACHD cohorts.

  • Open Access

    Routine Inflammation–Haemostasis Panel in Transvenous Lead Extraction: An Exploratory Prospective Single-Centre Cohort Study

    by Jakub K. Rokicki, Sylwia Wolff, Łukasz Januszkiewicz, Marcin Michalak, Katarzyna Czarzasta, Andrzej Cacko, Grzegorz Opolski, Marcin Grabowski

    Background/Objectives: Vascular and bleeding complications drive procedural mortality in transvenous lead extraction (TLE), yet contemporary risk scores include no pre-procedural laboratory measure of haemostasis or inflammation. We evaluated whether a routine inflammation–haemostasis panel (coagulation tests, blood counts and C-reactive protein [CRP]) and peri-procedural matrix metalloproteinase-9 (MMP-9) dynamics predict technical intra-procedural complexity. Methods: Fifty-four procedures in 53 consecutive patients at a single tertiary centre were analysed prospectively (50% infective; 86 leads). Technical complexity (prolonged procedure or fluoroscopy time; advanced-tool use) was modelled with the number of extracted leads as a predictor rather than an outcome component, in prespecified and stepwise-selected logistic models with bootstrap optimism correction. Results: The infective indication predicted extraction extent (≥2 leads: 70% vs. 22%) but not technical complexity: the time-based endpoint was not associated with the indication (OR 0.38, p = 0.16), and only cumulative lead dwell time predicted advanced-tool use (OR 1.27 per year; optimism-corrected area under the curve [AUC] 0.72). No routine panel variable predicted any technical endpoint, and none survived multiplicity correction. MMP-9 neither changed peri-procedurally nor differed between indications. A principal-component composite did not improve on CRP alone (AUC 0.66 vs. 0.69; p = 0.67), and the full panel’s apparent AUC (0.84) fell to 0.71 after optimism correction. Conclusions: No routine pre-procedural inflammation–haemostasis variable predicted technical complexity; the infective indication’s apparent association reflected guideline-mandated complete system removal—extraction extent—rather than technical difficulty. These exploratory findings support dwell-time- and anatomy-anchored risk scoring, directed haemostasis-activation markers rather than routine screening, and prospective studies capturing bleeding endpoints.

  • Open Access

    Hepatic Steatosis in Pulsed Field Ablation for Atrial Fibrillation: Prevalence, Liver Marker Concordance and Acute Procedural Characteristics

    by Maria Boszko, Bartosz Krzowski, Michał Gawlik, Alicja Skrobucha, Julia Szydlik, Mateusz Wawrzeńczyk, Karolina Mitrzak, Kacper Rutkowski, Karolina Ignaczak, Monika Gawałko, et al.

    Background/Objectives: Hepatic steatosis and metabolic dysfunction-associated steatotic liver disease (MASLD) are cardiometabolic phenotypes relevant to atrial fibrillation (AF), but their prevalence and acute procedural relevance in pulsed field ablation (PFA) are poorly defined. We estimated the prevalence of hepato-renal index (HRI)-detected hepatic steatosis, assessed liver marker concordance, and explored acute procedural characteristics. Methods: In this single-centre prospective study, 99 consecutive eligible patients undergoing first-time PFA for AF underwent B-mode hepatic ultrasound. Hepatic steatosis was defined a priori as HRI ≥ 1.28, measured offline by an investigator blinded to clinical and procedural data. HRI-based MASLD-compatible phenotype, Hepatic Steatosis Index (HSI), BARD score, and Fibrosis-4 index were analysed as secondary liver markers. Results: HRI-detected hepatic steatosis was present in 62/99 patients (62.6%, 95% CI 52.8–71.5), and HRI-based MASLD-compatible phenotype in 55/99 (55.6%, 95% CI 45.7–65.0). Agreement between HRI and HSI was poor (Cohen’s κ = 0.01; prevalence-adjusted bias-adjusted κ +0.06; positive agreement 62%). Acute pulmonary vein isolation was achieved in all patients. First-pass isolation was high in both groups (91.9% vs. 81.1%; p = 0.124). Most procedural metrics were similar. Fluoroscopy dose was modestly higher in patients with steatosis (median 226 vs. 207 mGy; p = 0.035), but this exploratory signal was inconsistent across sensitivity analyses. In-hospital complications were infrequent (4/99, 4.0%). Conclusions: In first-time PFA patients with feasible HRI assessment, hepatic steatosis was common, liver marker classifications showed limited patient-level agreement, and acute procedural conduct showed no consistent steatosis-specific signal. Long-term rhythm durability requires dedicated follow-up.

  • Open Access

    Gene Mutation in Patients with Familial Hypercholesterolemia and Response to Alirocumab Treatment—A Single-Centre Analysis

    by Joanna Rogozik, Jakub Kosma Rokicki, Marcin Grabowski, Renata Główczyńska

    Background: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder characterized by significantly elevated levels of low-density lipoprotein (LDL) cholesterol, which plays a major role in the progression of atherosclerosis and leads to a heightened risk of premature atherosclerotic cardiovascular disease. Methods: We have carried out an observational study on a group of 17 patients treated at the Outpatient Lipid Clinic from 2019 to 2024. Result: The most frequent mutation observed was found in the LDL receptor (LDLR) gene, which was identified in ten patients (58.8%). Five patients were identified to have a mutation in the apolipoprotein B (APOB) gene, whereas two patients had two points mutations, one in the LDLR, and the other in the APOB gene. The average age of patients with LDLR mutation was 54.8 (12.3); for APOB mutation it was 61.4 (9.3) and for patients with two points mutation it was 61.5 (14.8). The study results showed that at Week 12, individuals with LDLR-defective heterozygotes who were given alirocumab 150 mg every two weeks experienced a 63.0% reduction in LDL cholesterol levels. On the other hand, individuals with APOB heterozygotes experienced a 59% reduction in LDL cholesterol levels. However, in patients with double heterozygous for mutations in LDLR and APOB genes, there was a hyporesponsiveness to alirocumab, and the reduction in LDL-C was only by 23% in two individuals. Conclusions: In patients with a single mutation, there was a greater response to treatment with alirocumab in contrast to patients with double heterozygous mutation, who did not respond to treatment with PCSK9 inhibitors.


  • Open Access

    Employment of the Evolution RL sheath as a first-choice device shortens transvenous lead extraction time without affecting procedural safety and efficacy compared to its auxiliary use: Insights from the prospective multicenter EVO registry

    by Andrzej Przybylski, Dariusz Jagielski, Bruno Hrymniak, Marcin Michalak, Tomasz Wójcik, Paweł Syska, Tomasz Fabiszak, Jakub Rokicki, Barbara Małecka, Andrzej Ząbek, et al.

    Background. Transvenous lead extraction (TLE) is recommended in cases of local and systemic infections related to cardiac implantable electronic devices (CIEDs). Additionally, TLE is indicated in the event of lead damage or CIED malfunction. The extraction procedure is associated with a risk of life-threatening complications. Objectives. The aim of the EVO registry was to assess the safety and efficacy of birotational Evolution tool usage. Materials and methods. This registry study was prospectively conducted in 8 high-volume implantation centers in Poland. The study included 133 patients aged 63.5 +/- 15.1 years, and 76.69% were male. Indications for the procedure were: local or systemic infection (33.1%) and lead dysfunction (66.9%). The number of leads extracted varied from 1 (39.84%) to 3 (9.77%). Results. Clinical procedural success was achieved in 99.1% of cases. A total of 226 leads were extracted, and 206 used the Evolution system. Two procedural strategies were identified while using the Evolution system: (1) usage of locking stylet, propylene sheaths and the Evolution system (118 leads, 52%) - group A; (2) usage of locking styletand Evolution (88 leads, 39%) - group B. There were no differences in the number of complications between these 2 groups. The extraction time was significantly shorter (p = 0.02) in group B than in group A. Major complications occurred in 5.2% of cases with 2 intraprocedural deaths. Minor complications occurred in 1.5% of patients. Conclusions. The registry confirmed the efficacy and relative safety of the birotational Evolution sheath. Using the rotational sheath as a first attempt significantly reduces extraction time without compromising its safety.


  • Organization of the center for remote monitoring of implantable cardiac devices

    by Jakub K. Rokicki, Marcin Grabowski

    Remote monitoring of implantable devices is a solution allowing optimization of treatment in response to changes in the physiological parameters obtained by various sensors locates within the patients’ cardiovascular system. The technical efficiency of transmitting information at a distance, however, does not ensure the complete functionality of the system. The goals of care, i.e. preventing the negative consequences of arrhythmic events, prevention of exacerbation of heart failure, early detection of dysfunction of therapeutic systems, and many others, can only be achieved with the proper response of the staff of remote monitoring center. Organization of the remote monitoring center, the work culture should be based on three elements:competent and educated personnel updating their knowledgecorrect identification and education of patients – program participantstransparent and reliable information flowThe effective implementation of these three elements enables safe for patients and employees providing care using the latest technology in the field of electrotherapy.

  • Open Access

    The Use of Machine Learning Algorithms in the Evaluation of the Effectiveness of Resynchronization Therapy

    by Bartosz Krzowski, Jakub Rokicki, Renata Główczyńska, Nikola Fajkis-Zajączkowska, Katarzyna Barczewska, Mariusz Mąsior, Marcin Grabowski, Paweł Balsam

    Background: Cardiovascular disease remains the leading cause of death in the European Union and worldwide. Constant improvement in cardiac care is leading to an increased number of patients with heart failure, which is a challenging condition in terms of clinical management. Cardiac resynchronization therapy is becoming more popular because of its grounded position in guidelines and clinical practice. However, some patients do not respond to treatment as expected. One way of assessing cardiac resynchronization therapy is with ECG analysis. Artificial intelligence is increasing in terms of everyday usability due to the possibility of everyday workflow improvement and, as a result, shortens the time required for diagnosis. A special area of artificial intelligence is machine learning. AI algorithms learn on their own based on implemented data. The aim of this study was to evaluate using artificial intelligence algorithms for detecting inadequate resynchronization therapy. Methods: A total of 1241 ECG tracings were collected from 547 cardiac department patients. All ECG signals were analyzed by three independent cardiologists. Every signal event (QRS-complex) and rhythm was manually classified by the medical team and fully reviewed by additional cardiologists. The results were divided into two parts: 80% of the results were used to train the algorithm, and 20% were used for the test (Cardiomatics, Cracow, Poland). Results: The required level of detection sensitivity of effective cardiac resynchronization therapy stimulation was achieved: 99.2% with a precision of 92.4%. Conclusions: Artificial intelligence algorithms can be a useful tool in assessing the effectiveness of resynchronization therapy.


  • Defibrillation lead damage in a patient with MitraClip XTR device in tricuspid position

    by Marcin Michalak, Jakub Rokicki, Adam Rdzanek, Marcin Grabowski

    Transcatheter tricuspid valve interventions (TTVI) are newly emerged treatments for patients with severe tricuspid valve regurgitation. The most common TTVI technique is the edge-to-edge plication of tricuspid valve leaflets with MitraClip XTR device (Abbott, USA). Significant percentage of patients undergoing TTVI may have or require implantation of ventricular lead as part of pacing or implantable cardioverter-defibrillator (ICD) system in the future. The concomitant presence of both devices may pose a threat to inter-device interactions and significantly decrease lead durability. We present a case of 72-year-old male with early defibrillation lead failure referred for transvenous lead extraction (TLE). The single-chamber ICD with single-coil defibrillation lead (Plexa S 65, Biotronik, Germany) was implanted in November 2019 in primary prevention. One month later, the patient underwent MitraClip XTR implantation in mitral and tricuspid position due to severe symptomatic regurgitation (Panel A and see Supplementary material online, Video S1) with good echocardiographic and clinical effect. In September 2021, he received recurrent shocks from the ICD caused by short R–R intervals counted in VF zone (Panel B). The patient was qualified for TLE procedure. The lead was removed easily with simple traction. Due to high percentage of ventricular pacing, cardiac resynchronization therapy with defibrillator was implanted. Later, visual examination of the lead revealed severe insulation defect with conductor externalization (Panel C) at the site adjacent to tricuspid valve. To the best of our knowledge, this is the first case described, where lead failure was caused by collision with MitraClip device.